Twitxy
Saved
@CwynKate's profile picture
View on X

Kate Cwynarski

@CwynKate

#Lymphoma @UCLH. Professor UCL. Chair UK T cell lymphoma working group. Past chair UK CNSL study group. views my own. #WiL #lymsm
London, England Joined June 2017
604 Following 3.1K Followers 3.5K Posts

Latest posts 5

Kate Cwynarski @CwynKate
A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial

onlinelibrary.wiley.com/doi/full/10.11…
onlinelibrary.wiley.com A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial The AVAIL-T study, the first evaluation of programmed death ligand 1 (PD-L1) blockade in relapsed/refractory peripheral T-cell lymphomas (PTCL), demonstrated limited single agent activity with...
Kate Cwynarski @CwynKate
A pleasure to discuss management of SCNSL - where we have seen significant improvement in outcome but still many challenges & areas of unmet need

More clinical & translational research required

Thank you for inviting me @TheIACH @Mohty_EBMT & for many excellent questions 👏😊
Uriel Suárez Verified account @UsuarezMD Jun 3
Excellent webinar! Practical insights. Thank you, Professors. 👏🏻 @CwynKate @Mohty_EBMT @TheIACH
View quoted post on X
0 replies 7 reposts 23 likes 2.6K views View on X
Kate Cwynarski @CwynKate
Delighted to have the opportunity to discuss management of #SCNSL

Thank you @Mohty_EBMT @TheIACH
IACH Verified account @TheIACH May 28
🚨𝘑𝘰𝘪𝘯 𝘶𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘜𝘱𝘤𝘰𝘮𝘪𝘯𝘨 𝘐𝘈𝘊𝘏 𝘞𝘦𝘣𝘪𝘯𝘢𝘳:

𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝗖𝗡𝗦 𝗜𝗻𝘃𝗼𝗹𝘃𝗲𝗺𝗲𝗻𝘁 𝗶𝗻 𝗟𝗮𝗿𝗴𝗲 𝗕-𝗖𝗲𝗹𝗹 𝗟𝘆𝗺𝗽𝗵𝗼𝗺𝗮
𝘸𝘪𝘵𝘩 𝘒𝘢𝘵𝘦 𝘊𝘸𝘺𝘯𝘢𝘳𝘴𝘬𝘪

🗓️ 𝘞𝘦𝘥𝘯𝘦𝘴𝘥𝘢𝘺, 𝘑𝘶𝘯𝘦 3 2026
⏲️ 6 𝘗𝘔 𝘊𝘌𝘛, 12 𝘗𝘔 𝘕𝘠

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗙𝗥𝗘𝗘🔽
us06web.zoom.us/webinar/regist…

@Mohty_EBMT @CwynKate
View quoted post on X